

Corporate Factsheet

August 2026

Company Profile

OrbusNeich is a multinational medical device company specializing in interventional devices for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures. Headquartered in Hong Kong, China, OrbusNeich sells its products in more than 70 countries and regions worldwide. It is also actively expanding into structural heart disease area. OrbusNeich is listed on the Main Board of the Hong Kong Stock Exchange under the stock code 6929.

Employees worldwide


1,500+

Leadership


25+ Years of experience

Core management team

Innovation


215+

Granted patents & published patent applications globally

Bases


2 R&D facilities
3 Production centers

Capacity


2.1 million balloons and stents

Annual production capacity

Sales network


70+

Countries & regions

Excellent capabilities in R&D, Operation and Commercialization

R&D

R&D development

- Proprietary DCB
- Japan clinical is on track with first patient enrolled in July 2026
- Patient enrollment in the Mainland of China for NMPA registration and CE mark application will take place in 2H 2026

Product approval updates

- PMDA approvals: Sapphire ULTRA, Sapphire NC ULTRA;
- FDA approval: Teleport Glide;
- NMPA approvals: Scoreflex TRIO, Sapphire NC 24.


Operation

New facility construction

- The Hangzhou R&D and manufacturing facility is expected to progress steadily, with its final acceptance certificate expected in September 2026 and operations scheduled to commence by the end of 2027
- A new manufacturing facility, with a gross floor area of 1,500 square meters, will be established in Indonesia to cater to local demand.


Commercialization

- Sales network covering over 70 countries and regions
- Direct and distributor sales accounted for 60% and 40% of total sales in 1H 2026 respectively
- Direct sales network expanding to 15 markets following the transitioning of Benelux market to direct sales model
- Strengthened partnership with SonoScape by expanding IVUS product distribution to Indonesia



 Headquarters
 Hong Kong, China

 R&D and Production Center
 Shenzhen, China

 Production Center &
 EMEA Regional Headquarters
 Hoevelaken, the Netherlands

 Production Center
 Weil am Rhein, Germany

 Advanced Technology
 Laboratory
 Tokyo, Japan

Product portfolio




As of June 30, 2026



Key Financial Figures

Breakdown of revenue for 1H 2026



Corporate Headquarters

Address | Units 303 & 305, 3/F, Building 20E, Hong Kong Science Park, Shatin, N.T. Hong Kong
Phone | +852 2802 2288 Email | pr@orbusneich.com

www.OrbusNeich.com